Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds

Radiation Oncology

Naoyuki Shigematsu⁴  Mototsugu Oya¹  Ryuichi Kouta⁴  Yutaka Shiraishi⁴  Satoshi Seki⁴  Ryuichi Mizuno¹  Hirohiko Nagata¹  Etsuo Kunieda³  Jun Nakashima²  Akitomo Sugawara⁴ 

[1] Department of Urology, Keio University School of Medicine, Tokyo, Japan;Department of Urology, Tokyo Medical University, Tokyo, Japan;Department of Radiation Oncology, Tokai University School of Medicine, Isehara, Japan;Department of Radiology, Keio University School of Medicine, Tokyo, Japan

关键词: Seed;    Prostate cancer;    Migration;    ¹²⁵I;    Brachytherapy;   

Others  :  1223885
DOI  :  10.1186/1748-717X-6-130

 received in 2011-06-12, accepted in 2011-10-05,  发布年份 2011

【 摘 要 】

Background

The aim was to determine the incidence of seed migration not only to the chest, but also to the abdomen and pelvis after transperineal interstitial prostate brachytherapy with loose ¹²⁵I seeds.

Methods

We reviewed the records of 267 patients who underwent prostate brachytherapy with loose ¹²⁵I seeds. After seed implantation, orthogonal chest radiographs, an abdominal radiograph, and a pelvic radiograph were undertaken routinely to document the occurrence and sites of seed migration. The incidence of seed migration to the chest, abdomen, and pelvis was calculated. All patients who had seed migration to the abdomen and pelvis subsequently underwent a computed tomography scan to identify the exact location of the migrated seeds. Postimplant dosimetric analysis was undertaken, and dosimetric results were compared between patients with and without seed migration.

Results

A total of 19,236 seeds were implanted in 267 patients. Overall, 91 of 19,236 (0.47%) seeds migrated in 66 of 267 (24.7%) patients. Sixty-nine (0.36%) seeds migrated to the chest in 54 (20.2%) patients. Seven (0.036%) seeds migrated to the abdomen in six (2.2%) patients. Fifteen (0.078%) seeds migrated to the pelvis in 15 (5.6%) patients. Seed migration occurred predominantly within two weeks after seed implantation. None of the 66 patients had symptoms related to the migrated seeds. Postimplant prostate D90 was not significantly different between patients with and without seed migration.

Conclusion

We showed the incidence of seed migration to the chest, abdomen and pelvis. Seed migration did not have a significant effect on postimplant prostate D90.

【 授权许可】

   
2011 Sugawara et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Al-Qaisieh B, Carey B, Ash D, Bottomley D: The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:397-399.
• [2]Fuller DB, Koziol JA, Feng AC: Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy 2004, 3:10-19.
• [3]Reed DR, Wallner KE, Merrick GS, Arthurs S, Mueller A, Cavanagh W, Butler WB, Ford E, Sutlief SG: A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007, 6:129-134.
• [4]Saibishkumar EP, Borg J, Yeung I, Cummins-Holder C, Landon A, Crook J: Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:61-68.
• [5]Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S, Sylvester J, Griffin TW: Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 42:1063-1067.
• [6]Nag S, Beyer D, Friedland J, Grimm P, Nath R: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
• [7]Ankem MK, DeCarvalho VS, Harangozo AM, Hartanto VH, Perrotti M, Han K, Shih WJ, Malka E, White EC, Maggio R, et al.: Implications of radioactive seed migration to the lungs after prostate brachytherapy. Urology 2002, 59:555-559.
• [8]Chauveinc L, Osseili A, Flam T, Thiounn N, Rosenwald JC, Savignoni A, Cosset JM: [Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients]. Cancer Radiother 2004, 8:211-216.
• [9]Eshleman JS, Davis BJ, Pisansky TM, Wilson TM, Haddock MG, King BF, Darby CH, Lajoie WN, Oberg AL: Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys 2004, 59:419-425.
• [10]Grimm PBJ, Ragde HH, Sylvester J, Mate T: Migration of 125 I and 103Pd seeds to the lung after transperineal brachytherapy for prostate cancer. Endocurie/Hypertherm Oncol 1993, 9:50.
• [11]Kumar PP, Good RR: Vicryl carrier for I-125 seeds: percutaneous transperineal insertion. Radiology 1986, 159:276.
• [12]Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ: Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy 2004, 3:71-77.
• [13]Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML: Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 2000, 46:215-220.
• [14]Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J: Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 1995, 45:87-92.
• [15]Nag S, Vivekanandam S, Martinez-Monge R: Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997, 39:667-670.
• [16]Older RA, Synder B, Krupski TL, Glembocki DJ, Gillenwater JY: Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol 2001, 165:1590-1592.
• [17]Steinfeld AD, Donahue BR, Plaine L: Pulmonary embolization of iodine-125 seeds following prostate implantation. Urology 1991, 37:149-150.
• [18]Stone NN, Stock RG: Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Urology 2005, 66:119-123.
• [19]Sugawara A, Nakashima J, Shigematsu N, Kunieda E, Kubo A: Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds. Brachytherapy 2009, 8:52-56.
• [20]Davis BJ, Bresnahan JF, Stafford SL, Karon BL, King BF, Wilson TM: Prostate brachytherapy seed migration to a coronary artery found during angiography. J Urol 2002, 168:1103.
• [21]Davis BJ, Pfeifer EA, Wilson TM, King BF, Eshleman JS, Pisansky TM: Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol 2000, 164:1661.
• [22]Hau EK, Oborn BM, Bucci J: An unusual case of radioactive seed migration to the vertebral venous plexus and renal artery with nerve root compromise. Brachytherapy 2011, 10:295-298.
• [23]Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi H: Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy 2006, 5:127-130.
• [24]Nguyen BD: Cardiac and hepatic seed implant embolization after prostate brachytherapy. Urology 2006, 68(673):e617-679.
• [25]Nguyen BD, Egnatios GL: Prostate brachytherapy seed migration to the left testicular vein. Brachytherapy 2010, 9:224-226.
• [26]Nguyen BD, Schild SE, Wong WW, Vora SA: Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy 2009, 8:309-312.
• [27]Saito S, Nagata H, Kosugi M, Toya K, Yorozu A: Brachytherapy with permanent seed implantation. Int J Clin Oncol 2007, 12:395-407.
• [28]Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS: Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995, 22:209-234.
• [29]Wagner W, Willich N, Radmard A, Christ A, Fleig PW, Krukemeyer MG: [Seed migration to the vertebral venous plexus after prostate brachytherapy.]. Urologe A 2010, 49:1390-1392.
• [30]Bertoldo U, Enrichens F, Comba A, Ghiselli G, Vaccarisi S, Ferraris M: Retrograde venous bullet embolism: a rare occurrence-case report and literature review. J Trauma 2004, 57:187-192.
• [31]Mattox KL, Beall AC Jr, Ennix CL, DeBakey ME: Intravascular migratory bullets. Am J Surg 1979, 137:192-195.
• [32]Raghavendran K, Evans JT: Bullet migration within the inferior vena cava. South Med J 2003, 96:96-98.
• [33]Rehm C, Alspaugh JP, Sherman R: Bullet embolus to the right hepatic vein after a gunshot wound to the heart and its percutaneous retrieval. J Trauma 1988, 28:719-720.
• [34]Wallace KL, Slovis CM: Hepatic vein bullet embolus as a complication of left thoracic gunshot injury. Ann Emerg Med 1987, 16:102-104.
• [35]Helps EP, Mc DD: Observations on laminar flow in veins. J Physiol 1954, 124:631-639.
• [36]Miura N, Kusuhara Y, Numata K, Shirato A, Hashine K, Sumiyoshi Y, Kataoka M, Takechi S: Radiation pneumonitis caused by a migrated brachytherapy seed lodged in the lung. Jpn J Clin Oncol 2008, 38:623-625.
• [37]Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP: Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 2006, 5:262-265.
• [38]Saibishkumar EP, Borg J, Yeung I, Cummins-Holder C, Landon A, Crook JM: Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer. Brachytherapy 2008, 7:200-205.